Companies / BOC Sciences / Theralizumab
BOC Sciences

Theralizumab | BOC Sciences

Theralizumab is an anti-CD28 monoclonal antibody that has been developed as a potential immunomodulatory drug for the treatment of autoimmune diseases. Theralizumab activates T cells by binding to CD28 receptor irrespective of T-cell receptor activation.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.